Cyclosporine Drug Market To Reach $7.55 Billion by 2035
Cyclosporine drugs market is projected to grow from $4.5 billion in 2025 to $7.55 billion by 2035, expanding at a CAGR of 4.8% during the forecast period (2026–2035). Cyclosporine, a critical immunosuppressant, continues to play a vital role in organ transplantation and autoimmune disease management, driving steady market demand across developed and emerging healthcare systems. A key macro driver for the market is the rising number of organ transplant procedures globally. According to the World Health Organization (WHO), more than 150,000 organ transplants are performed annually worldwide, with kidney transplants accounting for the majority. Additionally, the U.S. Food and Drug Administration (FDA) has approved multiple cyclosporine-based ophthalmic products for dry eye disease, supporting expansion in the ophthalmic segment. Among product types, Ophthalmic Formulations are expected to witness the fastest growth due to the rising prevalence of dry eye syndrome.
Browse the full report description of “Cyclosporine Drugs Market Size, Share & Trends Analysis Report, By Product Type (Oral Formulations, Parenteral Formulations, Ophthalmic Formulations), By Application (Organ Transplantation, Autoimmune Diseases, Ophthalmic Disorders, Dermatological Disorders), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), Forecast Period (2026-2035)” at https://www.omrglobal.com/industry-reports/cyclosporine-drugs-market
Competitive Landscape
Key companies operating in the global cyclosporine drug market include AbbVie Inc., Novartis AG, Santen S. A., Sun Pharmaceutical Industries Limited, Teva Pharmaceutical Industries Ltd., and Others. These companies focus on product differentiation, generic portfolio expansion, and ophthalmic innovations to strengthen their market presence. Additionally, increasing emphasis on cost-effective formulations and improved drug delivery systems is shaping the competitive dynamics of the market.
Recent Developments
- In December 2025, Amneal Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) approved its Cyclosporine Ophthalmic Emulsion 0.05%, a sterile, preservative-free generic equivalent of Restasis. The approval, which targets a U.S. market valued at approximately $2.0 billion annually, supports the company’s expansion into complex ophthalmic therapies within its Affordable Medicines segment, with a commercial launch scheduled for the first quarter of 2026.
- In December 2025, Santen Pharmaceutical Co., Ltd. announced the launch of Verkazia® (Ciclosporin Eye Drops) in China for the treatment of severe vernal keratoconjunctivitis (VKC) in children and young adults. This launch follows the company's broader strategic initiatives in the Asia-Pacific region.
Market Coverage
- The market number available for – 2025-2035
- Base year- 2025
- Forecast period- 2026-2035
- Segment Covered-
- By Product Type
- By Application
- By Distribution Channel
- Regions Covered
- North America
- Europe
- Asia- Pacific
- Rest of the World
Competitive Landscape – AbbVie Inc., Novartis AG, Santen S. A., Sun Pharmaceutical Industries Limited, Teva Pharmaceutical Industries Ltd., and Others.
Key questions addressed by the report.
- What is the market growth rate?
- Which segment and region dominate the market in the base year?
- Which segment and region will project the fastest growth in the market?
- Who is the leader in the market?
- How are players addressing challenges to sustain growth?
- Where is the investment opportunity?
Global Cyclosporine Drug Market Report Segment
By Product Type
- Oral Formulations
- Parenteral Formulations
- Ophthalmic Formulations
By Application
- Organ Transplantation
- Autoimmune Diseases
- Ophthalmic Disorders
- Dermatological Disorders
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Cyclosporine Drug Market Report Segment by Region
North America
- United States
- Canada
Europe
- UK
- Germany
- Italy
- Spain
- France
- Russia
- Rest of Europe
Asia-Pacific
- China
- India
- Japan
- South Korea
- Australia and New Zealand
- ASEAN Economies
- Rest of Asia-Pacific
Rest of the World
- Latin America
- Middle East & Africa
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/cyclosporine-drugs-market